Analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock.
Ayala Pharmaceuticals Stock Up 4.6 %
Shares of ADXS stock opened at $0.56 on Thursday. The stock has a market capitalization of $5.97 million, a PE ratio of -0.07 and a beta of 1.63. The firm has a 50 day moving average of $0.67 and a two-hundred day moving average of $0.73. Ayala Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) earnings per share (EPS) for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Featured Articles
- Five stocks we like better than Ayala Pharmaceuticals
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- What Is WallStreetBets and What Stocks Are They Targeting?
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
